Skip to content

Elaine Schattner

writer, health care advocate, physician

  • about
  • academic
  • book
  • journalist
  • portfolio
  • patient advocate
  • speaker
  • contact

The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease

innovation, neurology, policy, regulation
as seen in Forbes

The FDA’s decision reflects a thoughtful, not knee-jerk approach to its mission, which is to protect the public from fraudulent and unsafe substances. What’s at issue is how well eteplirsen works. And that it’s too expensive.

Related

Duchenne muscular dystrophyeteplirsenFDA decisionSarepta

More Projects

  • Tragedy In A Clinical Trial: A Reminder That Biotech Is Not A Game

    Tragedy In A Clinical Trial: A Reminder That Biotech Is Not A Game

  • The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease

    The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease

  • ‘Until 20,’ A Film About A Young Cancer Patient’s End-Of-Life Decisions

    ‘Until 20,’ A Film About A Young Cancer Patient’s End-Of-Life Decisions

  • about
  • academic
  • book
  • journalist
  • portfolio
  • patient advocate
  • speaker
  • contact
Proudly powered by WordPress | Theme: Sketch by WordPress.com.